New repository aims to unlock secrets of rare, deadly cholesterol disease
NCT ID NCT01109368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study creates a database of health information and blood samples from up to 60 children and adults with homozygous familial hypercholesterolemia (hoFH), a rare genetic condition causing extremely high cholesterol from birth. Researchers will track participants over time to learn how the disease progresses and how different treatments affect cholesterol buildup in arteries. The goal is to improve future care and help design better clinical trials for this life-threatening disorder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this repository could help researchers develop better treatments and monitoring strategies for people with this rare, severe cholesterol disorder.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health for participants, and results may take years to influence care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medical College
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New registry tracks Real-World safety of cholesterol drug lomitapide
- New shot could help teens with rare, severe high cholesterol
- Worldwide effort to unlock secrets of rare cholesterol disease
- New drug shows promise for rare High-Cholesterol disease
- Experimental drug targets stubborn cholesterol in rare disease
- New shot aims to slash sky-high cholesterol in rare genetic disease